Silencing TMED2 suppresses cell growth and tumor progression in diffuse large B-cell lymphoma via inducing G0/G1 cell cycle arrest - Takeaways - MDSpire

Silencing TMED2 suppresses cell growth and tumor progression in diffuse large B-cell lymphoma via inducing G0/G1 cell cycle arrest

  • By

  • Wei Qian

  • Mingzhen Yang

  • May 1, 2026

  • 0 min

Share

  • 1

    TMED2 expression is significantly elevated in diffuse large B-cell lymphoma (DLBCL) tissues and cell lines.

  • 2

    Knockdown of TMED2 leads to reduced cell proliferation and induces G0/G1 phase cell cycle arrest in DLBCL.

  • 3

    TMED2 silencing enhances apoptosis, indicated by increased Annexin V-positive cells and elevated caspase-3/7 activity.

  • 4

    In vivo studies show that TMED2 knockdown markedly inhibits tumor growth in xenograft models.

  • 5

    TMED2 is identified as a potential prognostic biomarker and therapeutic target in DLBCL due to its role in tumor progression.

Original Source(s)

Silencing TMED2 suppresses cell growth and tumor progression in diffuse large B-cell lymphoma via inducing G0/G1 cell cycle arrest

  • by Wei Qian, Mingzhen Yang

  • May 1, 2026

Related Content

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Biotech exec Jeremy Levin on the industry’s strategic turning point

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential